Explore our grantees and awardees

Grant category: Standalone grants

Year: 2023

Geography: United Kingdom

Atopic dermatitis, also called atopic eczema, or just eczema, is a non-contagious, chronic skin disease, causing dry, patchy, and itchy skin. It affects up to 20% of children and up to 10% of adults. Of all skin diseases worldwide, it is the most common type, with a burden that remains a significant challenge for the people affected, their families, and societies.

Despite progress made in treating severe forms of atopic dermatitis, there is a need for high-quality information showing how many people per country have atopic dermatitis and how severe it is. With strong data, atopic dermatitis can be better understood and treated.

With a grant from the LEO Foundation, the Global Atopic Dermatitis Atlas, or GADA, will help address gaps in current data by creating and maintaining a living online atlas, where the newest research-based knowledge and data on atopic dermatitis, its prevalence, severity, and treatment are available in one place – collected and analyzed in the same way for all countries.

About GADA

The Global Atopic Dermatitis Atlas (GADA) is a worldwide, long-term project. GADA is led by Professor Carsten Flohr (St John’s Institute of Dermatology, King’s College London, UK) and is an initiative established by the International League of Dermatological Societies (ILDS) in 2022 in collaboration with supporting stakeholders:

• The International Alliance of Dermatology Patient Organizations/GlobalSkin 
• The International Eczema Council (IEC) 
• The International Society of Atopic Dermatitis (ISAD) 
• The European Task Force on Atopic Dermatitis (ETFAD)

Visit GADA’s website

Read more

Grant category: Standalone grants

Year: 2023

Geography: Denmark

The Costerton Biofilm Center (CBC) at Department of Immunology and Microbiology (ISIM), University of Copenhagen, is a world-leading interdisciplinary research center dedicated to exploring chronic infections caused by bacteria, including skin infections. The center runs two infrastructure facilities which are open to external users from basic, clinical, and industrial research. 

There is an urgent need in the center’s Biofilm Test Facility to replace an outdated confocal laser scanning microscope which can no longer be serviced. The grant from the LEO Foundation therefore hopes to provide this upgrade, the microscope a critical tool in the CBC’s pioneering work on understanding how the ability of bacteria to form biofilm is key to addressing antimicrobial resistance and developing novel antibacterial treatments.  

Grant category: Standalone grants

Year: 2023

Geography: United Kingdom

Psoriasis is a life-long and currently incurable immune-mediated skin disease affecting more than 60 million people worldwide. In addition to its cutaneous, stigmatizing manifestations, the disease is associated with other major medical conditions including depression, cardiovascular disease, diabetes, arthritis and cancer and can be construed as life-ruining. As such it represents a significant public health challenge. Despite remarkable advances in treatment options in some parts of the world, psoriasis continues to affect the quality of life of patients and impact health economics negatively.

GPA Phase III (2023-2026)

The GPA Phase III is focused on continued improvement of the understanding of the epidemiology of psoriasis and its incidence and prevalence at the global level. This third phase aims to build upon the previous achievements of the GPA Phase II. Here ambitions include:

• An extensive update to the GPA’s large international dataset to create and launch edition 3 of the GPA.
• To strengthen collaboration with the dermatology work stream of the Global Burden of Diseases (GBD).
• To conduct new epidemiological studies to enhance the GPA.
• To conduct new studies to improve knowledge about the comorbid disease burden of psoriasis.

Background

With a mission to ‘ensure that people with psoriasis, wherever they live in the world, have access to the best available care’, Professor Griffiths and the University of Manchester initiated the development of a Global Psoriasis Atlas in 2016. The GPA is a long-term iterative project, which was initiated in close collaboration with the WHO and international dermatology and psoriasis organisations. 

The LEO Foundation has been main funder of the development of the 1st edition of the GPA through a 3-year grant of DKK 6,370,000 from 2017 – 2020. The GPA project has in its first period (GPA Phase I) focused on research into the global prevalence and incidence of psoriasis – with the 1st edition of the GPA website launched on World Psoriasis Day 29 October 2019.

The LEO Foundation was also the main sponsor of GPA phase II, with a three-year grant of DKK 8,000,000 from 2020-2022. In this phase, the atlas-initiative has had a special focus on increasing its global outreach, including studies of psoriasis in Latin America, Malaysia, and Taiwan as well as on increasing and validating data on the association of psoriasis and cancer. Another important element of Phase II was to design and test a clinical diagnostic tool for health-care professionals globally, taking into account the different expressions of the disease, depending on skin colour. 

Visit the GPA website.

Grant category: Standalone grants

Year: 2022

Geography: Denmark

The Institute for Immunology and Microbiology is the host of the LEO Foundation’s major strategic initiative, the LEO Foundation Skin Immunology Center (SIC). ISIM has been established with flow cytometry and single cell sequencing as main areas of expertise and serves as a platform for integrative cell analysis.  

ISIM provides local and external research groups and biotech companies with access to highly specialized equipment for analysis using flow cytometry and state-of-the-art single cell sequencing, as well as highly specialized staff who are experts at analyzing samples in complex projects.  

In support of ISIM the LEO Foundation provides new equipment to the organization to upgrade technological options for cell and single cell analysis, to make it possible to implement new methods using new and existing equipment together, and to help ensure that the core facility can support experiments in the entirety of their pipeline – from initial idea formation to full-scale experiments.  

More information

Grant category: Standalone grants

Year: 2022

Geography: Denmark

SIC Springtime School is hosted annually by the LEO Foundation Skim Immunology Research Center (SIC) and has shown to be a great success over the two previous years. The international school is held at Hornbækhus on the North Coast of Zealand and forms part of SIC’s educational and career development activities – in 2022 representing 86 speakers, international students, and postdoc participants.  

The SIC Springtime School offers participants the opportunity to interact with leading scientists, providing for rich and positive learning experiences.  

More information

Grant category: Standalone grants

Year: 2022

Geography: Denmark

The SIC PhD Program aims to nurture the development of upcoming skin immunologists and to further tap into the collaborative possibilities of the research groups within the by the LEO Foundation Skim Immunology Research Center (SIC). 

The program features a 1+3-year structure for five PhD studies at the center. In their first year, students are onboarded into the program as Research Assistants, before eventually enrolling as full-time PhD students in their year two. 

The program sets to strengthen not only the collaborative nature of the center, but also allows for potentially high-gain projects to be set into motion. 

Grant category: Standalone grants

Year: 2021

Geography: Denmark

Add-on Grant for the Leo Foundation Skin Immunology Research Center. Herlev and Gentofte Hospital together with LEO Foundation Skin Immunology Research Center at the University of Copenhagen establish a new research program and biobank with skin tissue and blood samples from 3,000 patients with illnesses such as psoriasis and eczema. The biobank is the first of its kind and will help shed light on some of the most common skin diseases. The goal is to collect data from 3,000 patients with skin diseases and in the long term also making data and knowledge available for researchers around the world.

The research program is established by the LEO Foundation Skin Immunology Research Center at the University of Copenhagen and the Department of Dermatology and Allergy at Herlev and Gentofte Hospital.

The program is supported with DKK 40 million from the LEO Foundation and co-financed with DKK 20 million from Herlev and Gentofte Hospital and LEO Foundation Skin Immunology Research Center.

Read more

Grant category: Standalone grants

Year: 2021

Geography: Denmark

A new grant of DKK 15 million will enable the LEO Foundation Center for Cutaneous Drug Delivery (LFCCDD) at the Department of Pharmacy, University of Copenhagen to further strengthen its research on how drug permeation into and through the skin can be enhanced for improved treatment outcome.

The LEO Foundation Center for Cutaneous Drug Delivery was established in 2017 based on a 10-year grant of DKK 40 million from the LEO Foundation. The new DKK 15 million grant adds to the previous grant.

Read more

Grant category: Standalone grants

Year: 2020

Geography: United Kingdom

Psoriasis is a significant, life-long and currently incurable skin disease, which, according to the first edition of the Global Psoriasis Atlas (GPA), affects at least 60 million people worldwide.

The need to understand and uncover how psoriasis impacts both the individual and society at large is in demand. The Global Psoriasis Atlas is a long-term project that seeks to become the ‘go-to’ evidence-based resource within the understanding of psoriasis and its effects on people and society all over the World.

GPA Phase II (2020-2023)

The GPA Phase II  is focused on continued research to establish robust data that address existing knowledge gaps within psoriasis on epidemiology, improving diagnosis, comorbid disease and economic impact.

Furthermore, if sufficient and robust data are available, the plan is to perform a pilot implementation study as part of GPA Phase II.

Addressing these key areas and how they differ between countries and regions will support the aim to provide better access to care for people with psoriasis worldwide.

Background

With a mission to ‘ensure that people with psoriasis, wherever they live in the world, have access to the best available care. The grant for the first version of the GPA was granted to Professor Griffiths and the University of Manchester in 2016.

The LEO Foundation has been main funder of the development of the first edition of the GPA through a 3-year grant of DKK 6,370,000 from 2017 – 2020. The GPA project has in its first three years focused on research into the global prevalence and incidence of psoriasis – resulting in the first edition of the GPA website which can be accessed free of charge here: Global Psoriasis Atlas online

Grant category: Standalone grants

Year: 2019

Geography: Denmark

Researchers in immunology, cell biology and cancer were first movers in single-cell sequencing when they demonstrated a huge potential of this novel technology to unravel novel cell populations and disease heterogeneity.

This approach has gained further momentum fueled by new, exiting studies in neurobiology and rheumatology. So far, single-cell sequencing has not been used in relation to skin diseases – with few exceptions such as our new study on single-cell sequencing in cutaneous T cell lymphoma (CTCL) – the first paper of its kind – which was rapidly followed by three additional papers on single-cell sequencing in CTCL.

Moving from investigating an average of molecular changes in thousands or millions of cells to the study of changes in the transcriptome in single cells is critical to obtain a deeper and more precise understanding of disease heterogeneity and novel disease mechanisms. In other words, single-cell sequencing is expected to become the novel golden standard in all areas of research related to immunology and inflammation including the scientific focus area of the LEO Foundation Skin Immunology Research Center.

The “package” provides the sufficient capacity to conduct state-of-the-art single-cell analysis in the key areas of the LEO Foundation Skin Immunology Research Center. In order to get maximal advantage, value, and rapid implementation of the instruments, we will employ a novel protocol for this platform to run up to 5 different modalities (mRNA, TCRab, TCRgd, surface proteins, sample hashing and CRISPR lead sequences) in parallel to top-tune the technology.